Advertisement

Topics

Lilly Pulitzer Company Profile

20:26 EDT 19th September 2017 | BioPortfolio


News Articles [557 Associated News Articles listed on BioPortfolio]

Drugmaker Lilly beats Street 2Q forecasts, raises outlook

This Tuesday, July 17, 2012, file photo shows the Eli Lilly corporate headquarters in Indianapolis. Eli Lilly and Co.

Eli Lilly Pledges $52M to Life Sciences Partnership with Purdue

Injectable medications rank among Eli Lilly’s top-selling products. The Indianapolis drug giant is now scouting for new innovations in injectable medicine and it hopes to find them in its backyard. ...

Lilly Announces Plans to Close its Shanghai R&D Center

In a letter to China employees, Andrew Hodge, President, Lilly China, notified staff members that Lilly will close down its Shanghai R&D center. The center opened in 2012 and is located in Zhangji...

Eli Lilly appoints Leigh Ann Pusey as senior VP of corporate affairs and communications

Eli Lilly and Company, announced that Leigh Ann Pusey will be joining Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017. She will be a member of Lilly's e...

After job cuts in the U.S., Eli Lilly to create new jobs in Ireland

The Irish Independent reported that U.S. pharma giant Eli Lilly is to proceed with a €200m expansion at its Kinsale manufacturing site in County Cork, a major boost for the Government following a se...

Lilly Declares Third-Quarter 2017 Dividend

INDIANAPOLIS, June 19, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2017 of $0.52 per share on outstanding common s...

Lilly Migraine Drug Demonstrates Long-Term Safety Results in Study

NewsIHC 2017: Lilly's galcanezumab demonstrates positive long-term safety results for up to 12 months in patients with migraine. Lilly plans to submit a BLA to the FDA by year end followed by submissi...

Eli Lilly opens expanded biotechnology center in San Diego

Eli Lilly and Company has announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's new space will help foster and accelerate the discovery of medic...

Drugs and Medications [32 Associated Drugs and Medications listed on BioPortfolio]

Xigris [Eli Lilly and Company]

These highlights do not include all the information needed to use XIGRIS safely and effectively. See full prescribing information for XIGRIS.XIGRIS (drotrecogin alfa (activated)) injection, powder, ly...

Axid ar [Wyeth Consumer Healthcare]

Axid AR (nizatidine)

Gemzar [Eli Lilly and Company ]

These highlights do not include all the information needed to use GEMZAR safely and effectively. See full prescribing information for GEMZAR.GEMZAR (gemcitabine for injection) Powder, Lyophilized, For...

Humulin [Eli Lilly and Company]

HUMULIN 70/3070% HUMAN INSULIN ISOPHANE SUSPENSION AND 30% HUMAN INSULIN INJECTION (rDNA ORIGIN)100 UNITS PER ML (U-100)

Humulin [Eli Lilly and Company]

HUMULIN N NPH HUMAN INSULIN (rDNA ORIGIN)ISOPHANE SUSPENSION100 UNITS PER ML (U-100)

PubMed Articles [6 Associated PubMed Articles listed on BioPortfolio]

Obama's 'Minimally Invasive' ACA Could Use Clinton's Fine-Tuning.

The Princeton sociologist and Pulitzer Prize winner says that the law left the health care system largely intact. A Clinton presidency could mean important adjustments to the law, including addressing...

Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835.

A series of spirocyclic compounds inspired by Eli Lilly's phase 1 antidiabetic FFA1 receptor agonist LY2881835 was designed to include polar aromatic periphery groups and explore a possibility of buil...

Virtual screening and repositioning of inconclusive molecules of beta-lactamase Bioassays-A data mining approach.

This study focuses on the best possible way forward in utilizing inconclusive molecules of PubChem bioassays AID 1332, AID 434987 and AID 434955, which are related to beta-lactamase inhibitors of Myco...

The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.

In the past decade, the federal government has frequently investigated and prosecuted pharmaceutical manufacturers for illegal promotion of drugs for indications not approved by the Food and Drug Admi...

Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR(®)/ABASAGLAR(®)) approved in the European Union.

Basaglar(®)/Abasaglar(®) (Lilly insulin glargine [LY IGlar]) is a long-acting human insulin analogue drug product granted marketing authorisation as a biosimilar to Lantus(®) (Sanofi insulin glargi...

Clinical Trials [22 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen™ (glucagon injection) to Lilly Glucagon (glucagon for injection [rDNA origin]) for hypoglycemia ...

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.

Lilly's Emotional and Physical Symptoms of Depression

To assess the effectiveness of duloxetine administered once daily in patients with Major Depressive Disorder in a practice based setting

Lilly's Emotional and Physical Symptoms of Depression Study

To assess the effectiveness of duloxetine administered once daily in patients with Major Depressive Disorder in a practice-based setting

Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)

To assess the effectiveness of duloxetine administered once daily in patients with Major Depressive Disorder in a practice based setting

Companies [56 Associated Companies listed on BioPortfolio]

Lilly Pulitzer

Lilly USA

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and fro...

Lilly Corporate Center

Applied Molecular Evolution (AME) is a leader in applying directed molecular evolution to improve <!--LGfEGNT2Lhm-->healthcare by discovering, optimizing and developing human biotherapeutics. ...

Applied Molecular Evolution

Applied Molecular Evolution (AME) is a leader in applying directed molecular evolution to improve healthcare by discovering, optimizing and developing human biotherapeutics. Since its inception, AME...

Eli Lilly and Company

<!--LGfEGNT2Lhm-->Eli Lilly and Company is a leading, innovation-driven corporation committed to developing a growing portfolio of best-in-class and first-in-class pharmaceutical products that...

More Information about "Lilly Pulitzer" on BioPortfolio

We have published hundreds of Lilly Pulitzer news stories on BioPortfolio along with dozens of Lilly Pulitzer Clinical Trials and PubMed Articles about Lilly Pulitzer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lilly Pulitzer Companies in our database. You can also find out about relevant Lilly Pulitzer Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record